Alternative splicing of the pituitary adenylate cyclase-activating polypetide (PACAP) receptor contributes to function of PACAP-27.
Pituitary adenylate cyclase-activating polypeptide (PACAP)-27 and PACAP-38 are neuropeptides performing a variety of physiological functions. The PACAP-specific receptor PAC1 has several variants that result mainly from alternative splicing in the mRNA region encoding the first extracellular (EC1) domain and the third intracellular cytoplasmic (IC3) loop. To characterize the molecular forms of alternative splicing variants of PAC1, we examined the binding affinity and activation of two major second messenger pathways (cAMP production and changes in [Ca(2+)]( i )) by PACAP-27. Activation of cAMP was influenced by the variant in both of the EC1 domain and IC3 loops. In the N form in the EC1 domain, the suppressive effect of the HOP1 form in the IC3 loop was enhanced. Regarding the intracellular calcium mobilization assay, the rank order of the potency of PACAP-27 for the different PAC1 isoforms was S/HOP1>>N/R~S/R>>N/HOP1. In particular, PACAP-27 exhibited remarkable potency of calcium mobilization in the S/HOP1-expressing cells at sub-picomolar concentrations even though the affinities of PACAP-27 to the four PAC1 isoforms were not significantly different. This suggests the specific functions of PACAP-27 due to PACAP-27 preferring PAC1 activation, and leads in clarification of the pleiotoropic function of PACAP.
Ushiyama
Mina
M
Department of Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka, Kagoshima, Japan.
Ikeda
Ryuji
R
Yoshida
Morikatsu
M
Mori
Kenji
K
Kangawa
Kenji
K
Sugawara
Hideki
H
Inoue
Kazuhiko
K
Yamada
Katsushi
K
Miyata
Atsuro
A
D017398:Alternative Splicing; D000818:Animals; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D000242:Cyclic AMP / Q000378:metabolism; D051379:Mice; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000235:genetics / Q000378:metabolism*; D020033:Protein Isoforms / Q000235:genetics* / Q000378:metabolism*; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000235:genetics* / Q000378:metabolism*
D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020033:Protein Isoforms; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D000242:Cyclic AMP; D002118:Calcium
Biochem Biophys Res Commun. 1990 Jul 31;170(2):643-8
2383262
Int J Pept Protein Res. 1996 Oct;48(4):391-6
8919060
Mol Pharmacol. 2007 Jul;72(1):103-11
17442841
Endocrinology. 2002 Jul;143(7):2680-92
12072402
J Biol Chem. 1996 Sep 6;271(36):22146-51
8703026
Endocrinology. 1990 Jul;127(1):272-7
2361473
Gene. 1995 Oct 27;164(2):301-4
7590347
J Pharmacol Exp Ther. 2009 Oct;331(1):197-203
19602551
Endocrinology. 1991 Nov;129(5):2787-9
1935809
J Med Chem. 2009 May 28;52(10):3308-16
19413310
Neuron. 1992 Apr;8(4):811-9
1314625
J Biomol Screen. 2005 Dec;10(8):780-7
16234348
Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
2803320
J Pharmacol Exp Ther. 1997 Nov;283(2):478-87
9353360
J Biol Chem. 1996 Dec 13;271(50):32226-32
8943280
Peptides. 2007 Sep;28(9):1631-9
17574305
FEBS Lett. 1999 Sep 17;458(2):197-203
10481065
Regul Pept. 2004 Dec 15;123(1-3):147-53
15518905
Nature. 1993 Sep 9;365(6442):170-5
8396727
Eur J Pharmacol. 1997 Oct 29;338(1):35-42
9408001
Cardiovasc Res. 1996 Feb;31 Spec No:E153-9
8681340
J Cardiovasc Pharmacol. 1997 Feb;29(2):216-21
9057071
J Biol Chem. 1994 Jan 14;269(2):1290-3
8288592
J Biol Chem. 1996 Jul 19;271(29):17267-74
8663363
J Biol Chem. 2007 Mar 16;282(11):8079-91
17213203
Ann N Y Acad Sci. 2006 Jul;1070:586-90
16888230
Eur J Biochem. 1992 Sep 15;208(3):815-9
1327769
FEBS Lett. 1993 Nov 8;334(1):3-8
8224221
J Neuroendocrinol. 1999 Dec;11(12):941-9
10583729
EMBO J. 2005 Jan 26;24(2):325-35
15635449
Biochem Biophys Res Commun. 1990 May 16;168(3):1027-33
2346475
Eur J Pharmacol. 1996 Nov 21;315(3):289-96
8982667